Richard Aplenc, MD
CML Specialist
23 years treating Chronic Myeloid Leukemia
-min_e3cb2bac-bada-4763-af4d-b8693344fe16.jpg?alt=media&token=4889da58-0cd2-429a-af63-4f7835b1340e)
Clinical Expertise
- Chronic Myeloid Leukemia (CML)
- Novel therapies
About
Dr. Richard Aplenc is a Professor of Pediatrics in the Department of Pediatrics and a core faculty member of the Center for Pediatric Clinical Effectiveness at CHOP. He holds the Mai and Harry F. West Endowed Chair in Pediatric Research. Dr. Aplenc’s research focuses on improving the outcomes of children with cancer, particularly acute myeloid leukemia (AML.) His work involves the treatment of AML in children and the use of genetic data to predict treatment response to therapeutic interventions. Dr. Aplenc has NIH funded research efforts in pediatric AML focused on determining the genetic predictors of treatment response (specifically relapse and infection risk) and using administrative/billing data to augment NCI funded cooperative oncology group clinical trials. He is currently leading a genome-wide genotyping effort to discover genetic variations that change the risks of relapse, life-threatening infections, and heart complications in children treated for AML. He also leads several efforts to use administrative data sets to improve the care of children with AML, particularly focusing on antibiotic and intensive care use.
Location
Mayo Clinic Phoenix: 5881 E Mayo Blvd, Phoenix, AZ 85054, USA
Get the latest thought leadership on Chronic Myeloid Leukemia delivered straight to your inbox.
Subscribe to the weekly "HealthTree Community for Chronic Myeloid Leukemia Newsletter" for Chronic Myeloid Leukemia news, life with Chronic Myeloid Leukemia stories, Chronic Myeloid Leukemia clinical trials, Chronic Myeloid Leukemia 101 articles and events with Chronic Myeloid Leukemia experts.
HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.
Copyright © 2023 HealthTree Foundation. All rights reserved.
Tax ID 45-5354811